SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Anti-fibrotic effects of curcumin and some of its analogues in the heart.

Gorabi, AM; Hajighasemi, S; Kiaie, N; Rosano, GMC; Sathyapalan, T; Al-Rasadi, K; Sahebkar, A (2020) Anti-fibrotic effects of curcumin and some of its analogues in the heart. Heart Fail Rev, 25 (5). pp. 731-743. ISSN 1573-7322 https://doi.org/10.1007/s10741-019-09854-6
SGUL Authors: Rosano, Giuseppe Massimo Claudio

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (301kB) | Preview

Abstract

Cardiac fibrosis stems from the changes in the expression of fibrotic genes in cardiac fibroblasts (CFs) in response to the tissue damage induced by various cardiovascular diseases (CVDs) leading to their transformation into active myofibroblasts, which produce high amounts of extracellular matrix (ECM) proteins leading, in turn, to excessive deposition of ECM in cardiac tissue. The excessive accumulation of ECM elements causes heart stiffness, tissue scarring, electrical conduction disruption and finally cardiac dysfunction and heart failure. Curcumin (Cur; also known as diferuloylmethane) is a polyphenol compound extracted from rhizomes of Curcuma longa with an influence on an extensive spectrum of biological phenomena including cell proliferation, differentiation, inflammation, pathogenesis, chemoprevention, apoptosis, angiogenesis and cardiac pathological changes. Cumulative evidence has suggested a beneficial role for Cur in improving disrupted cardiac function developed by cardiac fibrosis by establishing a balance between degradation and synthesis of ECM components. There are various molecular mechanisms contributing to the development of cardiac fibrosis. We presented a review of Cur effects on cardiac fibrosis and the discovered underlying mechanisms by them Cur interact to establish its cardio-protective effects.

Item Type: Article
Additional Information: This is a post-peer-review, pre-copyedit version of an article published in Heart Failure Reviews. The final authenticated version is available online at: https://doi.org/10.1007/s10741-019-09854-6.
Keywords: C66, Cardiac fibrosis, Curcumin, Diferuloylmethane, J19, Anti-Inflammatory Agents, Non-Steroidal, Cell Differentiation, Curcumin, Fibrosis, Heart Failure, Humans, Myocardium, Myofibroblasts, Signal Transduction, Myocardium, Humans, Fibrosis, Curcumin, Anti-Inflammatory Agents, Non-Steroidal, Signal Transduction, Cell Differentiation, Heart Failure, Myofibroblasts, C66, Cardiac fibrosis, Curcumin, Diferuloylmethane, J19, Cardiovascular System & Hematology, 1102 Cardiorespiratory Medicine and Haematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Heart Fail Rev
ISSN: 1573-7322
Language: eng
Dates:
DateEvent
September 2020Published
11 September 2019Published Online
15 July 2019Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
943771National Institute for Medical Research DevelopmentUNSPECIFIED
PubMed ID: 31512150
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113707
Publisher's version: https://doi.org/10.1007/s10741-019-09854-6

Actions (login required)

Edit Item Edit Item